Trial Profile
The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Zoledronic acid (Primary) ; Calcium carbonate; Colecalciferol; Denosumab
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Acronyms AfterDmab
- 12 May 2021 Results (n=47) assessing duration of denosumab treatment affects the efficacy of subsequent zoledronate infusion, published in the Journal of Clinical Endocrinology and Metabolism.
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.
- 30 Sep 2018 Planned number of patients changed from 90 to 55.